2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Immunology, Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

1316 Improved outcomes in pediatric immune thrombotic thrombocytopenic purpura (iTTP) treated with caplacizumab in addition to standard of care

Connor Tompkins, MD, Candelaria O'Farrell, MD2, Emma Stevens, MD3, Sarah E Sartain, MD4, Clay Cohen, MD5, Lisa Hensch, MD6, Mark Zobeck, MD7, Emily Marie Harris, MD8, Taylor Kim, MD9, Amanda Grimes, MD10
1 Baylor College of Medicine, Houston, United States
2 Baylor College of Medicine, Houston, United States
3 Boston Children’s Hospital, Boston, Massachusetts, United States
4 Baylor College of Medicine, Houston, United States, Texas Children's Hospital, Houston, Texas, United States
5 Baylor College of Medicine, Houston, United States, Texas Children's Hospital, Houston, Texas, United States
6 Baylor College of Medicine, Houston, Texas, United States
7 Baylor College of Medicine, Houston, United States, Texas Children's Hospital, Houston, Texas, United States
8 Boston Children’s Hospital, Boston, Massachusetts, United States
9 Children's Hospital of Los Angeles, Los Angeles, Texas, United States
10 Baylor College of Medicine, Houston, United States

Background: The efficacy of caplacizumab in the treatment of adults with immune thrombotic thrombocytopenic purpura (iTTP) has been well-demonstrated, resulting in its incorporation into standard iTTP management in adults. There are no comparative studies of caplacizumab in the pediatric population. Despite this, caplacizumab received FDA approval for treatment of pediatric patients 12 years of age and older in 2026 and is being incorporated into upfront treatment of iTTP at major pediatric medical centers alongside current standard of care (SOC), which includes therapeutic plasma exchange (TPE), corticosteroids, and anti-B cell therapy. Evaluation of the efficacy, safety, and long-term outcomes of adding caplacizumab to SOC in this population is warranted. 

 

Objective: We aimed to compare the clinical outcomes of children in a recent multi-institutional cohort treated for iTTP with current SOC alone to those treated with SOC plus caplacizumab therapy.  

 

Design/Methods: All patients under 21 years of age, diagnosed and treated for iTTP at 3 large tertiary referral care centers between August 2012 and May 2024, were identified and retrospectively reviewed for the outcomes of interest, in accordance with IRB-approved protocols. Included patients had a clinical diagnosis of iTTP, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) enzyme level < 10%, and presence of an ADAMTS13 inhibitor. Patients with hereditary TTP were excluded. Patients were split into two groups: those who received SOC and those who received SOC plus caplacizumab within 72 hours of diagnosis. Primary outcomes were in-hospital mortality and occurrence of iTTP relapse. Secondary outcomes were time to clinical response (defined as normalization of platelet count and LDH), overall mortality, days of hospital and  stay, duration of steroid treatment, days of TPE, time to ADAMTS13 recovery (defined as ADAMTS13 enzyme level > 20%), bleeding frequency, thrombosis and stroke frequency, and time to ADAMTS13 inhibitor elimination. P values were reported with the Wilcoxon rank-sum test for continuous variables and the Fisher’s exact test for categorical variables. 

 

Results: Pediatric patients treated with caplacizumab in addition to SOC (n=8) compared to those treated with SOC alone (n=14) had a lower median time to clinical response (4 vs 11 days, p < .01), fewer days of TPE therapy, (5 vs 7 days, p = 0.02), and a lower rate of clinical relapse (0% vs 50%, p = 0.02). One patient receiving caplacizumab developed a deep venous thrombosis and one developed a stroke, while no patients who received SOC alone developed thrombosis. There was no statistically significant difference in time to ADAMTS13 recovery, mortality, duration of steroid treatment, bleeding frequency, time to ADAMTS13 inhibitor elimination, or length of hospital or ICU stay.  

 

Conclusion: Our data suggest that upfront addition of caplacizumab to the SOC treatment of iTTP in children significantly reduces the time to disease resolution and also decreases the frequency of recurrence. This is consistent with adult data and supports the incorporation of caplacizumab into standard clinical management of children with iTTP. However, the increased incidence of thrombotic events among patients receiving caplacizumab in this study merits further investigation in a larger cohort. 

 

Connor Tompkins, MD: No relevant conflicts of interest to declare.